Contract manufacturing news round-up

By Natalie Morrison

- Last updated on GMT

Related tags: Pharmacology

Contract manufacturing news round-up
Outsourcing-Pharma presents a round-up of the latest contract manufacturing headlines in the industry, including news from Nanohale, Fleming and Trophogen.

Protein formulation specialist Nanohale ​has acquired Scil Technology​’s CDMO biz, as well as the R&D (research and development) section of the company.

Under the deal, Nanohale will incorporate the new services offered by Scil into its subsidiary Formycon​.

The company hopes Scil’s offering in protein drug development, manufacturing and analytics, will complement its own.

“The completion of this transaction marks a significant broadening of the product and service portfolio of the Nanohale Group, and will facilitate the further transition from a pure technology-based company into a globally operating specialty pharmaceutical company,”​ said Nicolas Combé, CFO of Nanohale.

Scil Technology will keep its tissue regeneration projects operating as an independent company, including its lead dental and orthopedic programs, which were outlicensed to Medtronic and Sanofi.

Fleming ​is hunting for buyers for its Midwestern manufacturing facilities, after selling the rights to several of its products.

The firm has “excess capacity”​ after selling its branded products Ocean, Nephrocaps, Magonate and ProBarimin QT to neurology and dermatology drugs marketing company Valeant.

OTC maker Fleming says it will now focus on it’s manufacturing and development services for specialty pharmaceutical companies.

The company will also continue to manufacture and market ThyroShield, one of two FDA-approved potassium iodide medicines used in nuclear emergencies to block the thyroid gland from absorbing radioactive iodine.

Advanced BioScience Laboratories​ (ABL) has inked a contract manufacturing deal with Trophogen​ over its rhFSH human follicle-stimulating hormone analog.

The deal will see a technology transfer of Trophogen’s lead hair growth compound – originally licensed from the National Institutes of Health – in the build up to its anticipated Phase I and II trials, in 2014.

ABL will produce rhFSH for the studies, and will provide scale-up services, as well as conducting an engineering run.

“Trophogen is very pleased that the lead product of its large portfolio of more potent, more efficacious and longer acting human and bovine recombinant superagonist analogs will be commercialized with ABL's expert assistance,”​ said Bruce Weintraub, president and COO of Trophogen.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Keys To A Successful Rapid Commercial Launch

Keys To A Successful Rapid Commercial Launch

Catalent Pharma Solutions | 21-Oct-2020 | Insight Guide

Pharma and biotech companies are dedicating resources to new treatments with the hope of helping patients. The quicker they can get products to patients,...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us

Products

View more

Webinars